Solvonis acquires Intellectual Property from Awakn Life Sciences, affecting pipeline references.

Solvonis renames treatments for mental health and addiction

UK-based biotechnology firm Solvonis Therapeutics PLC has announced changes to the names of its novel treatments for mental health and substance use disorders.

As part of the firm’s acquisition of Awakn Life Sciences Corp., the changes are:

·  AWKN-001 is now known as SVN-001

·  AWKN-002 is now known as SVN-002

·  AWKN-SDN-14 is now known as SVN-SDN-14

SVN-001, now in phase 3, combines IV ketamine with copyrighted manualised relapse prevention cognitive behavioural therapy to target the biological and psychosocial aspects of alcohol use disorder in the UK.

SVN-002, now in phase 2b planning, is a novel combination therapy consisting of a patent-pending proprietary esketamine oral thin film with manualised psycho-social support to treat moderate to severe alcohol use disorder in the US.

SVN-SDN-14 is a series of serotonin, dopamine and noradrenaline modulators under pre-clinical investigation by Solvonis, for the treatment of post-traumatic stress disorder.

The acquisition of Awakn’s clinical-stage assets will allow Solvonis to strengthen its position in the mental health therapeutics marketplace, with enhanced expertise, financial capacity and market capitalisation. The transaction is expected to be completed in the second quarter of 2025.